These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9027766)

  • 1. Should hyperlipidaemia in dialysis patients be treated?
    Wheeler DC
    Nephrol Dial Transplant; 1997 Jan; 12(1):19-21. PubMed ID: 9027766
    [No Abstract]   [Full Text] [Related]  

  • 2. [Dyslipidemia in renal failure].
    Fujioka T; Ueno T; Matsumoto T; Watanabe H
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():118-23. PubMed ID: 15250280
    [No Abstract]   [Full Text] [Related]  

  • 3. Importance of hyperlipidaemia and therapy in renal patients.
    Wanner C
    Nephrol Dial Transplant; 2000; 15 Suppl 5():92-6. PubMed ID: 11073280
    [No Abstract]   [Full Text] [Related]  

  • 4. Major and minor risk factors for cardiovascular disease in continuous ambulatory peritoneal dialysis patients.
    Prichard S
    Perit Dial Int; 1999; 19 Suppl 2():S133-7. PubMed ID: 10406507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patients.
    Fox CS; Longenecker JC; Powe NR; Klag MJ; Fink NE; Parekh R; Coresh J;
    Clin Nephrol; 2004 May; 61(5):299-307. PubMed ID: 15182124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs?
    Weissgarten J; Zaidenstein R; Fishman S; Dishi V; Michovitz-Koren M; Averbukh Z; Golik A
    Perit Dial Int; 1999; 19(2):180-2. PubMed ID: 10357195
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyperlipidemia of chronic renal failure.
    Kaysen GA
    Blood Purif; 1994; 12(1):60-7. PubMed ID: 7986478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular problems in the choice of dialysis therapy for the elderly.
    Maiorca R
    Contrib Nephrol; 1994; 106():74-83. PubMed ID: 8174382
    [No Abstract]   [Full Text] [Related]  

  • 9. [Lipid disturbances in patients with chronic kidney failure treated conservatively with peritoneal dialysis].
    Lososowska R; Rutkowski B
    Pol Arch Med Wewn; 1997 Jun; 97(6):570-7. PubMed ID: 9441294
    [No Abstract]   [Full Text] [Related]  

  • 10. [Abnormality of lipid metabolism in patients on continuous ambulatory peritoneal dialysis (CAPD)].
    Saito E; Matsuda N; Tanahashi Y; Makise J; Kanayama M
    Rinsho Byori; 1986 Sep; 34(9):1083-7. PubMed ID: 3795543
    [No Abstract]   [Full Text] [Related]  

  • 11. Treating dyslipidemia to slow the progression of chronic renal failure.
    Palmer BF; Alpern RJ
    Am J Med; 2003 Apr; 114(5):411-2. PubMed ID: 12714133
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular risk factors and blood pressure control in continuous ambulatory peritoneal dialysis.
    Lameire N
    Perit Dial Int; 1993; 13 Suppl 2():S394-5. PubMed ID: 8399620
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperlipidemia in patients with chronic renal disease.
    Kasiske BL
    Am J Kidney Dis; 1998 Nov; 32(5 Suppl 3):S142-56. PubMed ID: 9820472
    [No Abstract]   [Full Text] [Related]  

  • 14. Bimonthly update: lipidology. Hyperlipidaemia and cardiovascular disease.
    Sussekov AV; Stekolschikova OD
    Curr Opin Lipidol; 2000 Oct; 11(5):559-62. PubMed ID: 11048899
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis.
    Lameire N; Bernaert P; Lambert MC; Vijt D
    Kidney Int Suppl; 1994 Dec; 48():S31-8. PubMed ID: 7700039
    [No Abstract]   [Full Text] [Related]  

  • 16. Does the choice of renal replacement therapy adversely affect the hypercoagulability associated with renal disease?
    Assouad M; Eknoyan G
    Am J Nephrol; 1998; 18(3):175-8. PubMed ID: 9627031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor?
    Rabelink TJ
    Nephrol Dial Transplant; 2004 Jan; 19(1):23-6. PubMed ID: 14671033
    [No Abstract]   [Full Text] [Related]  

  • 18. [Lipid anomalies during renal insufficiency: consequences on the progression of renal insufficiency and cardiovascular risk].
    Moulin B
    Nephrologie; 2000; 21(7):339-41. PubMed ID: 11200605
    [No Abstract]   [Full Text] [Related]  

  • 19. Options in dialysis therapy: significance of cardiovascular findings.
    Wizemann V; Timio M; Alpert MA; Kramer W
    Kidney Int Suppl; 1993 Feb; 40():S85-91. PubMed ID: 8445844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of hypertension in dialysis patients and renal transplant recipients].
    Małyszko J; Fryc J; Myśliwiec M
    Przegl Lek; 2005; 62(7):694-7. PubMed ID: 16463704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.